Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$VCEL Interesting Weekly chart show top of boll band 4.96, one nice press release and we open above that, or until then, we should trend up to it for the Jan 3rd, 2017 PDUFA, all jmho
Thanks for posting the charts, awesome
$VCEL Couple google searches regarding Japan Partnerships
https://www.google.com/#q=vericel++takeda
https://www.google.com/#q=takeda+pharmaceuticals
https://www.google.com/#q=takeda+pharmaceuticals%2C+stem+cell%2C+vericel
VCEL
$VCEL, hints a Japan partnership being pursued in this webcast 24 minute mark regarding regulatory and partnerships
http://wsw.com/webcast/ladenburg2/vcel/
VCEL
$VCEL link to twitter chat
https://twitter.com/search?q=%24vcel&src=typd
VCEL
$VCEL DD post from another board, very nice
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125436797
VCEL
The $VCEL twitter chat is heating up with Excitement for the MACI PDUFA Jan 3 2017
$VCEL looking to push over the $3's today in this market down day,
Which imho, shows again the strength of VCEL uptrending.
Awesome lasers for the $VCEL link, just what I was looking for.
http://www.4-traders.com/VERICEL-CORP-18635051/consensus/
Excellent tool website for great info and charts
Thanks, don't we have two analyst calling VCEL 12 month target of 11 or 12 dollars?
$VCEL, lookie at the AMGN chart, who knows, give it time, I have time
Just did a chart on AMGN on yahoo and put the chart on MAX, wowsa
$VCEL Thanks, I monitor the careers activity everyday, they rock
Less than a month to the $4.50's area, imho, a good press release and it's Instant
Twitter/$vcel has a good feed on updates going on.
500mil market cap is what I am waiting for.
Jobs fill,bigly, they fill the positions, nicely
http://vcel.com/careers/
VCEL An announcement of a partnership could push this to double digits, only +-24 mil os
https://finance.yahoo.com/quote/VCEL/key-statistics?p=VCEL
http://www.nasdaq.com/symbol/vcel
Thoughts ?
VCEL 6 bucks no brainer, 8 bucks probable, 11 bucks reachable in one year, jmho FDA approval by Jan 3rd, 2017 for MACI in motion
For me, this is getting exciting. Waiting for the 500 mil market cap to come along.
VCEL going to break the 200dma today?
lasers, any chance we could get a buy out? Wonder what pps it would be at? Unless they announce a partnership soon? Something is in the cards.
$VCEL may we trend up to $6.00's by Jan 2017 and go double digits on FDA approval of MACI
VCEL website revamped
http://vcel.com/
Media news coverage on Vericel VCEL
http://www.foxnews.com/health/2016/06/02/scientists-re-grow-skin-young-man-who-suffered-third-degree-burns.html
Are we expecting any FDA announcements sometime this year on either MACI or the ixmyelocel-T
VCEL Amazing that VCEL can grow a an entire body of skin from a postage stamp skin sample for burn victims.
What is your thought on this concept?
lasers, do we have any catalyst coming?
Are we expecting any FDA type news coming from VCEL? in the next 8 weeks?
Harr, are you thinking there is a chance that this could get revived, are efforts to do this in the making?
VCEL That is why I got dry powder money , nailed some cheapies today and if the shorties play tomorrow, I am going to scoop up a handful. like lasers said, this is an AMGN in the making,
How would you like to lay in a hospital bed w/DCM and a doctor tells you that you have have a 37% better chance of survival over nothing, with XmylecotT, would you turn it down because Jason Napadono or Adam F makes twitter comments like the Establishment doing its typical games in the stock market for their paycheck?
hmmmmmm, no brainer
XmylecolT is now Proven. and FDA orphan drug status
11:46 am Vericel presents results from its Phase 2b ixCELL-DCM clinical study of ixmyelocel-T in patients with advanced heart failure due to ischemic dilated cardiomyopathy (shares halted) (VCEL) :
The trial met its primary endpoint with patients in the ixmyelocel-T group having a 37 percent reduction in all-cause deaths, cardiovascular hospitalizations, or unplanned outpatient and emergency department visits to treat acute decompensated heart failure during the 12 months following treatment compared to the placebo group (p=0.0344). The primary endpoint was driven by a reduction in both all-cause deaths and cardiovascular hospitalizations. In the primary endpoint without procedure-related events, three percent of patients in the ixmyelocel-T group died and 38 percent had cardiovascular hospitalizations one or more times, compared to 14 percent and 47 percent, respectively, in the placebo group. All deaths were adjudicated to be due to cardiovascular causes.
•With respect to the secondary endpoints of the trial, the components of the primary endpoint were also analyzed using the Win ratio in a hierarchical manner to incorporate both the incidence and timing of the endpoint components. The Win ratio result of 1.56 showed that more often ixmyelocel-T was the "winner" in that the time to death, left ventricular assist device placement, heart transplantation or time to cardiovascular hospitalization was shorter for placebo-treated patients, but this difference did not reach statistical significance. The time to first event was longer in the ixmyelocel-T group compared to placebo, but was not statistically significant. There were no significant structural changes in left ventricle cavity size or left ventricular ejection fraction as measured by echocardiogram in either the ixmyelocel-T or placebo groups. Both treatment groups had an improvement in the NYHA class and six minute walk test, with no statistical difference between the groups at month 12 using last observation carried forward.
•Overall, there were fewer adverse events and serious adverse events in the ixmyelocel-T group compared to the placebo group. Adverse events included those typically related to catheterization or injection procedures.
•The ixCELL-DCM trial showed a statistically significant reduction in clinical events driven by both cardiac mortality and cardiac hospitalizations at 12 months compared to placebo. These results are consistent with two previous Phase 2a studies which showed that ischemic DCM patients treated with ixmyelocel-T experienced fewer major adverse cardiovascular events during follow up compared to control patients.
Brutal day, thought the news was good.
I can't wait for VCEL to announce some partnership news.
Shouldn't be long, the writing is on the wall since they did that
15M non-dilutive financing, sounds like they just needed some bridge cash until the partnership begins with big pharma the real money rolls in.
Love the new homepage on VCEL website, News on homepage
http://vcel.com/
I had a Sanofi pharm rep come into my office yesterday and I explained the Monday news topic that we are coming upon and the response was OMG, stem cell heart injection for DCM going to be huge
HOPING for positive VCEL news tomorrow pre market, that AMGN 20 yr chart is amazing, btw
Love to see a morning trading halt (pending News) coming Friday or Monday for the big bopper announcement.
That will make the shorts quiver. lol
Ixmyelocel-T is going to be HUGE.
6 minutes to $6.00, lets see the shorts eat a nice gapper
15 minutes to the 6's, hold on to those bootstraps
Noticing the volume is kicking in a bit, 5.78 HOD
VCEL If they announce a partnership, wonder if the shorts will cover in panic?
Amen, I fully agree with your point of view, I expect volatility here and am in it for the long haul. Accumulating on the dips.
Lasers, shouldn't that have driven the pps down, how can such a large short be placed and the pps goes up?